Controlling paroxysmal atrial fibrillation by a combination of amiodarone and flecainide: Description of a case with 15-year follow-up

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 4, 1996, Pages 333-338

  Altamirano, Jaime ^a   Gallik, Donna M ^a   Singh, Bramah N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amiodarone; Class III antiarrhythmic drugs; Flecainide; Paroxysmal atrial fibrillation; Sinus rhythm; Sotalol

Indexed keywords

EID: 0005160837     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100409     Document Type: Article

References (18)

1. Antman EA. Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. J Cardiovasc Electrophysiol 6:962, 1995.
2. Singh BN. Expanding indications for the use of class III agents in patients at high risk for sudden death. J Cardiovas Electrophysiol 6:887, 1995.
3. Kowey PR, Levine JH, Herre JM, Pacifico Aet al.Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 92:3255, 1995.
4. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone and post-MI patients. Circulation 88:764, 1993.
5. Singh BN, Vaughan Williams EM The effect of amiodarone. a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39:657, 1970.
6. Olsson B, Brorson L, Varnauskas E. Class III antiarrhythmic action in man: observations from monophasic action potential recordings and amiodarone treatment. Br Heart J 35:1255, 1973.
7. Middlekauf HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med 116:1017, 1992.
8. Chun S, Sager PT, Stevenson WG, Nademanee K, Middlekauf HR, Singh B. Amiodarone is highly effective in maintaining NSR in refractory atrial fibrillation/flutter. Am J Cardiol 76:47, 1995.
9. Rosenbaum MB, Chiale PA, Halpern MSet al.Clinically efficacy of amiodarone as n anti-arrhythmic agent. Am J Cardiol 38:934, 1976.
10. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 106:870, 1983.
11. Gold RL, Haffajee CL, Charos G, Solan K, Baker S, Albert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 57:124, 1986.
12. Horowitz LN, Spielman SR, Greenspan AM. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to conventional antiarrhythmic therapy. J Am Coll Cardiol 6:1402, 1985.
13. Brodsky MA. Amiodarone for the maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of dilated left atrium. Am J Cardiol 60:572, 1987.
14. Blevins RD, Kerin NZ, Benaderet D. Amiodarone in the management of refractory atrial fibrillation. Arch Int Med 147:1404, 1987.
15. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 57:124, 1981.
16. Gosselink ATM, Crijns HJGM, Van Gelder I, Lee KIG. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267:3282, 1992.
17. Singh BN. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J 14:14, 1993.
18. Wang Z, Pelletier LC, Talajic M, Nattel SS. Effects of flecainide and quinidine on human atria action potentials role of rate dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 82:277, 1990.